Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free GDTC Stock Alerts

CytoMed Therapeutics (GDTC) Short Interest Ratio & Short Volume

CytoMed Therapeutics logo
$1.21 +0.07 (+6.14%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CytoMed Therapeutics Short Interest Overview

As of May 29, 2026, CytoMed Therapeutics (GDTC) had a short interest of 67,963 shares sold short, representing 0.57% of the public float. This marks a -4.40% decrease in short interest since the prior report. The short interest ratio (days to cover) is 2.3, meaning it would take 2.3 days of the average trading volume of 322,904 shares to cover all short positions.

Current Short Interest
67,963 shares
Previous Short Interest
71,090 shares
Change Vs. Previous Month
-4.40%
Dollar Volume Sold Short
$79.52 thousand
Short Interest Ratio
2.3 Days to Cover
Last Record Date
May 29, 2026
Outstanding Shares
11,830,000 shares
Short Percent of Float
0.57%
Today's Trading Volume
2,641 shares
Average Trading Volume
322,904 shares
Today's Volume Vs. Average
1%
Short Selling CytoMed Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for CytoMed Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

GDTC Short Interest Over Time

GDTC Days to Cover Over Time

GDTC Percentage of Float Shorted Over Time

CytoMed Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/29/202667,963 shares $79.52 thousand -4.4%0.6%2.27 $1.17
5/15/202671,090 shares $82.46 thousand +4.3%0.6%2.69 $1.16
4/30/202668,135 shares $67.93 thousand -5.3%0.6%11.22 $1.00
11/14/202522,080 shares $43.28 thousand +31.3%N/A0.13 $1.96
10/31/202516,818 shares $37.00 thousand -83.8%N/A0.09 $2.20
10/15/2025103,700 shares $233.33 thousand +263.9%2.3%1.5 $2.25
9/30/202528,500 shares $56.72 thousand -33.6%0.6%1.7 $1.99
9/15/202542,900 shares $91.16 thousand +28.1%1.0%3.3 $2.13
8/31/202533,500 shares $68.01 thousand -11.8%0.8%3 $2.03
8/15/202538,000 shares $68.40 thousand -2.3%0.9%3.1 $1.80
7/31/202538,900 shares $73.72 thousand -27.3%0.8%3.6 $1.90
7/15/202553,500 shares $109.14 thousand -20.6%1.1%4.6 $2.04
6/30/202567,400 shares $151.65 thousand +18.7%1.4%4.6 $2.25
6/15/202556,800 shares $120.53 thousand -12.9%1.2%3.5 $2.12
5/31/202565,200 shares $151.26 thousand -11.1%1.2%3.7 $2.32
5/15/202573,300 shares $171.52 thousand -4.8%1.4%4.1 $2.34
4/30/202577,000 shares $182.49 thousand -12.2%1.5%4.2 $2.37
4/15/202587,700 shares $205.22 thousand -6.8%1.8%4.4 $2.34
3/31/202594,100 shares $207.02 thousand -6.8%2.0%0.5 $2.20
3/15/2025101,000 shares $250.48 thousand -21.0%2.1%0.5 $2.48
2/28/2025127,800 shares $350.17 thousand -13.5%3.2%0.6 $2.74
2/15/2025147,800 shares $378.37 thousand -22.5%3.1%0.7 $2.56
1/31/2025190,600 shares $503.18 thousand -15.6%4.0%1 $2.64
1/15/2025225,900 shares $494.72 thousand +174.8%4.7%1.1 $2.19
12/31/202482,200 shares $279.48 thousand +31.1%1.7%0.4 $3.40
12/15/202462,700 shares $170.26 thousand -17.1%1.3%3.2 $2.72
11/30/202475,600 shares $177.66 thousand -1.6%1.6%4.4 $2.35
11/15/202476,800 shares $166.99 thousand -19.4%1.6%6.3 $2.17
10/31/202495,300 shares $229.67 thousand -17.9%2.0%7.7 $2.41
10/15/2024116,100 shares $241.49 thousand -2.4%2.5%10 $2.08
9/30/2024118,900 shares $186.67 thousand -3.1%2.5%1.7 $1.57
9/15/2024122,700 shares $184.05 thousand -2.3%2.6%1.9 $1.50
8/31/2024125,600 shares $186.05 thousand +5.3%2.7%1.9 $1.48
8/15/2024119,300 shares $206.39 thousand -9.4%2.5%1.8 $1.73
7/31/2024131,600 shares $238.20 thousand +240.9%2.8%2 $1.81
7/15/202438,600 shares $77.20 thousand -1.8%0.8%0.6 $2.00
6/30/202439,300 shares $81.74 thousand +1.3%0.8%10.1 $2.08
6/15/202438,800 shares $73.72 thousand +9.9%0.8%8.6 $1.90
5/31/202435,300 shares $76.25 thousand -8.3%0.8%5.8 $2.16
5/15/202438,500 shares $85.86 thousand -10.3%1.0%5.4 $2.23
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel

👉 Unlock the ticker now and get it completely free.
4/30/202442,900 shares $90.52 thousand +8.9%1.1%3 $2.11
4/15/202439,400 shares $79.59 thousand +11.6%1.0%1.6 $2.02
3/31/202435,300 shares $76.60 thousand +82.9%0.9%1.2 $2.17
3/15/202419,300 shares $41.11 thousand No Change0.5%0.4 $2.13
2/29/202419,300 shares $38.79 thousand -15.7%0.5%0.4 $2.01
2/15/202422,900 shares $57.48 thousand +593.9%0.6%0.4 $2.51
1/31/20243,300 shares $11.68 thousand -58.2%0.1%0.1 $3.54
1/15/20247,900 shares $32.63 thousand -54.3%0.2%0.2 $4.13
12/31/202317,300 shares $84.77 thousand +1,135.7%0.4%0.5 $4.90
12/15/20231,400 shares $4.75 thousand -63.2%0.0%0.1 $3.39
11/30/20233,800 shares $14.02 thousand +245.5%0.1%0.6 $3.69
11/15/20231,100 shares $4.41 thousand -54.2%0.0%0.2 $4.01
10/31/20232,400 shares $8.95 thousand -50.0%0.1%0.2 $3.73
10/15/20234,800 shares $16.94 thousand -20.0%0.1%0.3 $3.53
9/30/20236,000 shares $21 thousand -25.9%0.2%0 $3.50
9/15/20238,100 shares $30.46 thousand -5.8%0.2%0 $3.76
8/31/20238,600 shares $28.98 thousand +30.3%0.2%0 $3.37
8/15/20236,600 shares $24.88 thousand -50.0%0.2%0 $3.77
7/31/202313,200 shares $57.16 thousand -92.2%0.3%0 $4.33
7/15/2023169,600 shares $736.06 thousand +198.6%4.3%0.3 $4.34
6/30/202356,800 shares $173.24 thousand +24.6%1.5%0.1 $3.05
6/15/202345,600 shares $129.50 thousand -27.2%1.2%0.3 $2.84
5/31/202362,600 shares $170.90 thousand +67.8%1.8%0.3 $2.73
5/15/202337,300 shares $114.88 thousand No Change1.1%0.1 $3.08

GDTC Short Interest - Frequently Asked Questions

Short interest is the volume of CytoMed Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 29th, traders have sold 67,963 shares of GDTC short. 0.57% of CytoMed Therapeutics' shares are currently sold short. Learn More on CytoMed Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GDTC shares currently have a short interest ratio of 2.3. Learn More on CytoMed Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.57% of CytoMed Therapeutics' floating shares are currently sold short.

CytoMed Therapeutics saw a decline in short interest in the month of May. As of May 29th, there was short interest totaling 67,963 shares, a decline of 4.4% from the previous total of 71,090 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.57% of CytoMed Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to CytoMed Therapeutics: Dogwood Therapeutics, Inc (0.19%), Xilio Therapeutics, Inc. (2.72%), Metagenomi, Inc. (5.56%), Estrella Immunopharma, Inc. (0.20%), Mereo BioPharma Group plc - Sponsored ADR (5.47%), Genenta Science S.p.A. Unsponsored ADR (1.89%), Edesa Biotech, Inc. (3.55%), aTyr Pharma, Inc. (21.85%), Hyperion DeFi, Inc. (5.49%), Actuate Therapeutics, Inc. (9.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($81.27 billion), Invesco QQQ ($49.06 billion), iShares Russell 2000 ETF ($23.61 billion), Western Digital Corporation ($16.93 billion), Sandisk Corporation ($15.61 billion), Salesforce Inc. ($11.65 billion), SPDR S&P Biotech ETF ($10.52 billion), Nebius Group N.V. ($10.24 billion), Lumentum Holdings Inc. ($8.74 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($8.21 billion). View all of the most shorted stocks.

Short selling GDTC is an investing strategy that aims to generate trading profit from CytoMed Therapeutics as its price is falling. GDTC shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for CytoMed Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GDTC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GDTC, twice per month. The most recent reporting period available is May, 29 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like GDTC:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:GDTC) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Elon’s new "tollbooth"
The upcoming SpaceX IPO - reported for June 12 - is valued at $1.75 trillion. But one analyst says fighting ov...
Weiss Ratings | Sponsoredtc pixel